- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01397669
Characteristics of Immunity in Gut Mucosa, Spinal Fluid, Lymph Node and Blood of HIV Negative Thais and Thais With HIV Infection
To compare the immunophenotyping and immunochemistry in the gut mucosa of HIV negative and non-acute HIV-infected adults
- To compare the immunophenotyping of the gut mucosa to that of the peripheral blood in HIV negative and in non-acute HIV-infected subjects
- To compare the immunophenotyping of the peripheral blood in HIV negative and non-acute HIV-infected adults to the findings from acutely HIV-infected subjects in the WRAIR#1494/RV254/ SEARCH 010 study
- To compare immunologic markers in the genital compartment compared to the peripheral blood in HIV negative and non-acute HIV-infected adults to the findings from acutely HIV-infected subjects in the WRAIR#1494/RV254/ SEARCH 010 study
- Archive samples for immunologic and virologic testing
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will provide control samples for immunologic and virologic investigations from HIV negative and non-acute HIV-infected subjects to compare to subjects with acute HIV infection in WRAIR#1494/RV254/SEARCH 010 study. These control samples will allow for correct scientific interpretation of the immunologic changes seen in acute HIV infection in the peripheral blood, gut and genital compartments.
Subjects will be recruited at the Thai Red Cross Anonymous Clinic (TRCAC) and Chulalongkorn University Hospital. Eligible subjects will undergo a one-time flexible sigmoidoscopy and biopsy at Chulalongkorn University Hospital. They will have a total of approximately 60 ml of blood draw for immunophenotyping and storage. Genital secretion will be collected in subjects who agree to this optional procedure.
It will take approximately 12 months to complete the study. Each subject will have two visits: the screening visit and the enrollment visit (within 15 days of screening visit). Subjects may also be co-enrolled in other study protocols provided blood volumes are within acceptable limits.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nitiya Chomchey, RN
- Phone Number: 110 662 254 2566
- Email: nitiya.c@searchthailand.org
Study Locations
-
-
-
Bangkok, Thailand
- Recruiting
- Thai Red Cross AIDS Research Center
-
Contact:
- Nitiya Chomchey, RN
- Phone Number: 110 662 254 2566
- Email: nitiya.c@searchthailand.org
-
Principal Investigator:
- Jintanat Ananworanich, M.D.,Ph.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 50 years old
- HIV negative subjects must have negative results by 4th generation EIA and NAT (Aptima)
- HIV positive subjects must have a positive 4th generation EIA and a positive less sensitive EIA.
- Understand the study and sign informed consent form. Persons who cannot read will have the consent form read to them by a study staff and they can give informed consent by using thumb print.
Exclusion Criteria:
- Have gastrointestinal disorders or gastrointestinal symptoms that require endoscopy for diagnostic purposes or have systemic disorders, which include but may not be limited to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus or psoriasis, that in the judgment of investigators could cause colon mucosa to be abnormal on biopsy
- Active AIDS-defining opportunistic infection (OI) within 30 days prior to entry for HIV-positive subjects. Subjects must be off all acute treatments for OI for at least 14 days prior to entry. Subjects on maintenance or prophylactic therapy for AIDS-related OIs will be eligible.
- Have platelet count < 150,000 count/ml or PT, PT/PTT > the upper limit of normal (ULN) or INR > 1.1
- Have self-reported bleeding disorder
- Untreated syphilis infection
- Abnormal screening neurological examination suggestive of central neurological findings if planning to participate in the lumbar puncture
- Positive urine pregnancy test
- Persons who have a history of a medical or psychiatric disorder by investigator's interview and physical examination according to standard practices, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: HIV infection and non HIV infection
|
Eligible subjects will undergo a flexible sigmoidoscopy and biopsy, lumbar puncture, lymph node biopsy at Chulalongkorn University Hospital.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of HIV and non-HIV related clinical events
Time Frame: It will take approximately 24 months to complete the study.
|
It will take approximately 24 months to complete the study.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the immunophenotyping of the gut mucosa
Time Frame: Approximately 24 months to complete the study.
|
Approximately 24 months to complete the study.
|
the immunophenotyping of the peripheral blood
Time Frame: approximately 24 months to complete the study
|
approximately 24 months to complete the study
|
immunologic markers in the genital compartment
Time Frame: approximately 24 months to complete the study
|
approximately 24 months to complete the study
|
the immunophenotyping of the CSF
Time Frame: approximately 24 months to complete the study
|
approximately 24 months to complete the study
|
immunologic markers in the lymph node
Time Frame: approximately 24 months to complete the study
|
approximately 24 months to complete the study
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jintanat Ananworanich, MD, Department of Retrovirology USAMC-AFRIMS (SARCH office)
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- WRAIR#1751 /RV304/ SEARCH013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on Colon biopsy, lymph node biopsy, lumbar puncture
-
Duke UniversityCompletedProstate CancerUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedBreast Neoplasm Female
-
University of California, San FranciscoNational Institutes of Health (NIH)Recruiting
-
Gangnam Severance HospitalCompletedNeoadjuvant Chemotherapy | Micrometastases
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingConjunctival Melanoma | Porocarcinoma | Ocular Surface Squamous Neoplasia | Merkel Cell Carcinoma, Unspecified | Ocular Sebaceous Carcinoma | Ocular Basal Cell CarcinomaItaly
-
Bulent Ecevit UniversityRecruiting
-
Professor Fernando Figueira Integral Medicine InstituteCompletedUterine Cervical Neoplasms | Uterine NeoplasmsBrazil
-
The Christie NHS Foundation TrustWithdrawnSquamous Cell Carcinoma of the Anus
-
Jewish General HospitalMcGill University Health Centre/Research Institute of the McGill University...RecruitingSentinel Lymph Node | Cutaneous Squamous Cell CarcinomaCanada
-
Cliniques universitaires Saint-Luc- Université...Unknown